Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MBX 4291 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| MBX 4291 (Part A) | EXPERIMENTAL | Participants will be administered single ascending doses of MBX 4291, or matching placebo. |
| MBX 4291 (Part B) | EXPERIMENTAL | Participants will be administered multiple ascending doses of MBX 4291, or matching placebo. |
| MBX 4291 (Part C) | EXPERIMENTAL | Participants will be administered multiple ascending doses of MBX 4291, or matching placebo. |
| Placebo | PLACEBO_COMPARATOR | Participants will be administered single or multiple ascending doses of placebo. |
| Name | Type | Description |
|---|---|---|
| MBX 4291 | DRUG | MBX 4291 will be administered subcutaneously (SC) |
| Placebo | DRUG | Placebo: Placebo will be administered subcutaneously (SC) |
Inclusion Criteria: * Age of \>18 to ≤65 years at the time of signing the informed consent. * Has a BMI of ≥30 to \<50 kg/m2 at screening and baseline. * Weight-stable, i.e., no more than ±5% change in body weight for at least 3 months prior to screening and between screening and baseline. Exclusi...
Top 20 of 33 competitors